Terazosin
Product Images NDC 10544-289

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 10544-289). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure1)

The text describes data from Study 1, presented in Figure 1. The graph shows the mean change in the total symptom score and mean increase in peak flow rate from baseline for patients taking Terazosin or a placebo over a period of three months. The table above the graph provides the baseline values for the patients. The results indicate that Terazosin is more effective than the placebo in reducing total symptom score and increasing peak flow rate, with statistical significance indicated.*

FDA Label Image

Formula 2 (Figure2)

The text describes a figure labeled as Figure 2 showing the mean change in total symptom score from baseline in a long-term, open-label, non-placebo controlled study with 194 participants. The graph indicates that there was a significant improvement in symptoms over a period of 30 weeks, with a mean change from baseline of approximately 4%. There is also a note indicating that the difference was statistically significant (p <005) when compared to baseline, and that the mean baseline score was 10.7.*

FDA Label Image

Figure 3 (Figure3)

This is a figure from a long-term, open-label, non-placebo controlled study showing the mean change in peak flow rate from baseline. The figure includes data points at different time points (0, 1, 2, 3, 6, 12, 15, 16, 21, 24, 27, and 30 months) and indicates that there was a statistically significant improvement in peak flow rate compared to baseline (p<0.05). The mean baseline peak flow rate was 9.9.*

FDA Label Image

Label (Label Terazosin Caps 10mg Bpi(10544 289 30) Apotex(60505 0118 0) Rev2)

These are Terazosin Capsules of strengths 10mg, packaged in a bottle containing 30 capsules. It is a prescription medicine and should be stored at room temperature. The Lot# is BPO000000D and it was packaged by Blanhaim Pharmacal Inc. The text also provides information about the manufacturer, dosage and warnings about keeping it out of reach of children. There are also details about the equivalent of Fefazosi Hydrochloride in the capsules; however, there are some typos and inconsistent spellings in the text.*

FDA Label Image

Formula (Formula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.